Commonwealth Equity Services
XFOR icon

Commonwealth Equity Services’s X4 Pharmaceuticals XFOR Stock Holding History

Commonwealth Equity Services’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-842
Closed -$6K – 4369
2025
Q1 		$6K Hold
842
– – ﹤0.01% 4163
2024
Q4 		$19K Hold
842
– – ﹤0.01% 4046
2024
Q3 		$17K Buy
842
+5
+0.6% +$104 ﹤0.01% 4010
2024
Q2 		$15K Hold
837
– – ﹤0.01% 3982
2024
Q1 		$35K Hold
837
– – ﹤0.01% 3928
2023
Q4 		$21K Sell
837
-55
-6% -$1.34K ﹤0.01% 3815
2023
Q3 		$29K Buy
892
+142
+19% +$6.19K ﹤0.01% 3709
2023
Q2 		$44K Hold
750
– – ﹤0.01% 3679
2023
Q1 		$19 Hold
750
– – ﹤0.01% 3678
2022
Q4 		$22K Buy
+750
New +$35.5K ﹤0.01% 3593

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Commonwealth Equity Services's XFOR Position: Q2 2025 in Review

Commonwealth Equity Services sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 842 shares — an estimated $6K sold.

Commonwealth Equity Services first reported a position in XFOR in Q4 2022 and held it in 10 quarters. The position peaked at $44K in Q2 2023. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

  • Commonwealth Equity Services reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Commonwealth Equity Services sold 842 X4 Pharmaceuticals shares in Q2 2025, an estimated $6K.
  • Commonwealth Equity Services first reported a position in X4 Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • Commonwealth Equity Services's X4 Pharmaceuticals position peaked at $44K in Q2 2023.
  • 51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on Commonwealth Equity Services's 13F filing for Q2 2025, filed 6 Aug 2025.